In one paragraphArticle in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Dimitra TriantafillidiLaboratory of Genetics, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, 26504 Patras, Greece.ORCID 0009-0009-1340-5924 Vasiliki TziouvaraLaboratory of Genetics, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, 26504 Patras, Greece.
Alexandros PontikasLaboratory of Genetics, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, 26504 Patras, Greece.ORCID 0009-0007-5834-645X Adam AkritidisLaboratory of Genetics, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, 26504 Patras, Greece.
Charalabos AntonatosLaboratory of Genetics, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, 26504 Patras, Greece.ORCID 0000-0002-5967-9367 Aikaterini ZacharopoulouDepartment of Dermatology-Venereology, Faculty of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, 16121 Athens, Greece.
Aikaterini TsiogkaDepartment of Dermatology-Venereology, Faculty of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, 16121 Athens, Greece.
Ileana-Afroditi KleidonaDepartment of Dermatology-Venereology, Faculty of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, 16121 Athens, Greece.ORCID 0000-0003-0352-9228 Katerina GrafanakiDepartment of Dermatology-Venereology, School of Medicine, University of Patras, 26504 Patras, Greece.ORCID 0000-0002-6569-1928 Alexandra ChrysospathiDepartment of Dermatology, University General Hospital Larissa, University of Thessaly, 41334 Larissa, Greece.
Niki NtavariDepartment of Dermatology, University General Hospital Larissa, University of Thessaly, 41334 Larissa, Greece.ORCID 0000-0001-9071-9876 Elli KampraDepartment of Dermatology, University General Hospital Larissa, University of Thessaly, 41334 Larissa, Greece.
Sophia GeorgiouDepartment of Dermatology-Venereology, School of Medicine, University of Patras, 26504 Patras, Greece.
Efterpi ZafiriouDepartment of Dermatology, University General Hospital Larissa, University of Thessaly, 41334 Larissa, Greece.ORCID 0000-0002-6594-7292 Stamatis GregoriouDepartment of Dermatology-Venereology, Faculty of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, 16121 Athens, Greece.ORCID 0000-0002-7585-1032 Yiannis VasilopoulosLaboratory of Genetics, Section of Genetics, Cell Biology and Development, Department of Biology, University of Patras, 26504 Patras, Greece.ORCID 0000-0002-3167-7642 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
BACKGROUND/
objectivesWe conducted the first pharmacogenetic investigation of atopic dermatitis in a cohort of 43 Greek patients, focusing on key variants within the IL6/JAK/STAT signaling axis, a pathway central to inflammation and therapeutic targeting.
methodsPatients receiving dupilumab, JAK inhibitors, or topical corticosteroids were prospectively evaluated, with treatment response assessed by changes in the Eczema Area and Severity Index over four months. Targeted genotyping of
resultsAcross the full cohort, no robust pharmacogenetic effects were detected, while baseline disease severity was the strongest predictor of absolute clinical improvement. However, stratified analyses revealed a significant association between the
conclusionsAlthough limited by sample size, these findings suggest potential treatment-specific pharmacogenetic effects within the IL6 pathway, supporting further investigation in larger cohorts to inform personalized therapeutic strategies in eczema.
Indexed as
Dermatitis, AtopicInterleukin-6Receptors, Interleukin-6AdultAntibodies, Monoclonal, HumanizedFemaleGreeceHumansJanus Kinase 1Janus Kinase InhibitorsMaleMiddle AgedPharmacogeneticsPharmacogenomic TestingPolymorphism, Single NucleotideSignal TransductionAntibodies, Monoclonal, HumanizeddupilumabIL6 protein, humanIL6R protein, humanInterleukin-6JAK1 protein, humanJanus Kinase 1Janus Kinase InhibitorsReceptors, Interleukin-6atopic dermatitisdupilumabeczemapharmacogeneticsresponse to therapyupadacitinib
Identifiers
PMID42195032
PMCPMC13205716
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390